115 related articles for article (PubMed ID: 18376798)
21. Pathologic characteristics of prostatic adenocarcinomas: a mapping analysis of Korean patients.
Song SY; Kim SR; Ahn G; Choi HY
Prostate Cancer Prostatic Dis; 2003; 6(2):143-7. PubMed ID: 12806373
[TBL] [Abstract][Full Text] [Related]
22. Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation.
Omar EA; Behlouli H; Chevalier S; Aprikian AG
Prostate; 2001 Nov; 49(3):191-9. PubMed ID: 11746264
[TBL] [Abstract][Full Text] [Related]
23. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma.
Petrescu A; Mârzan L; Codreanu O; Niculescu L
Rom J Morphol Embryol; 2006; 47(2):143-6. PubMed ID: 17106522
[TBL] [Abstract][Full Text] [Related]
25. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
27. Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum.
Jovanović I; Todorović V; Milosavljević T; Micev M; Pesko P; Bjelović M; Mouzas Y; Tzardi M
Vojnosanit Pregl; 2005 Dec; 62(12):879-85. PubMed ID: 16375215
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis.
Suzuki Y; Nakano T; Kato S; Ohno T; Tsujii H; Oka K
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):231-6. PubMed ID: 15337561
[TBL] [Abstract][Full Text] [Related]
29. p21WAF1/CIP1 expression in primary lung adenocarcinomas: heterogeneous expression in tumor tissues and correlation with p53 expression and proliferative activities.
Takeshima Y; Yamasaki M; Nishisaka T; Kitaguchi S; Inai K
Carcinogenesis; 1998 Oct; 19(10):1755-61. PubMed ID: 9806155
[TBL] [Abstract][Full Text] [Related]
30. The expression of proliferating cell nuclear antigen, p53, p21, and apoptosis in primary gastric lymphoma.
Aoyagi K; Kohfuji K; Yano S; Murakami N; Miyagi M; Takeda J; Shirouzu K
Surgery; 2002 Jul; 132(1):20-6. PubMed ID: 12110791
[TBL] [Abstract][Full Text] [Related]
31. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.
Sinik Z; Alkibay T; Ataoglu O; Biri H; Sözen S; Deniz N; Karaoglan U; Bozkirli I
Int J Urol; 1997 Nov; 4(6):546-51. PubMed ID: 9477181
[TBL] [Abstract][Full Text] [Related]
32. p21 expression in colorectal carcinomas: a study on 103 cases with analysis of p53 gene mutation/expression and clinic-pathological correlations.
Girlando S; Slomp P; Caffo O; Amichetti M; Togni R; Dvornik G; Tomio L; Galligioni E; Dalla Palma P; Barbareschi M
Virchows Arch; 1999 Dec; 435(6):559-65. PubMed ID: 10628797
[TBL] [Abstract][Full Text] [Related]
33. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
Rigaud J; Tiguert R; Decobert M; Hovington H; Latulippe E; Laverdiere J; Larue H; Lacombe L; Fradet Y
Prostate; 2004 Feb; 58(3):269-76. PubMed ID: 14743466
[TBL] [Abstract][Full Text] [Related]
34. Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy.
Ljung G; Egevad L; Norberg M; Holmberg L; Nilsson S; Busch C
Prostate; 1997 Jul; 32(2):99-105. PubMed ID: 9215397
[TBL] [Abstract][Full Text] [Related]
35. Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
Colecchia M; Frigo B; Del Boca C; Guardamagna A; Zucchi A; Colloi D; Leopardi O
J Clin Pathol; 1997 May; 50(5):384-8. PubMed ID: 9215120
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas.
Soini Y; Pääkkö P; Nuorva K; Kamel D; Lane DP; Vähäkangas K
Virchows Arch A Pathol Anat Histopathol; 1992; 421(3):223-8. PubMed ID: 1413488
[TBL] [Abstract][Full Text] [Related]
37. The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Joshi US; Chen YC; Du W; Smith DW; Arlauskas P; Crissman JD; Vaitkevicius VK; Sarkar FH
Cancer; 1997 Aug; 80(3):372-81. PubMed ID: 9241070
[TBL] [Abstract][Full Text] [Related]
38. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
Skirnisdottir I; Seidal T
Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
[TBL] [Abstract][Full Text] [Related]
39. A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma.
Doganavsargil B; Simsir A; Boyacioglu H; Cal C; Hekimgil M
BJU Int; 2006 Mar; 97(3):644-8. PubMed ID: 16469041
[TBL] [Abstract][Full Text] [Related]
40. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.
Kwak C; Jin RJ; Lee C; Park MS; Lee SE
BJU Int; 2002 Feb; 89(3):303-9. PubMed ID: 11856116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
